Business Wire

CO-OPTIV-SECURITY

3.6.2019 20:07:03 CEST | Business Wire | Press release

Share
Optiv Security Doubles Down On Client Success with New Services Approach, Business and Engagement Model; Further Advances Ability to Help Global Clients Optimize, Integrate and Operationalize Cybersecurity

While industries are being completely reinvented at an ever-accelerating pace, the overall approach to cybersecurity has not similarly evolved to address the new security challenges presented by rapid digital transformation. Talent shortages, expanding attack surfaces, and constant breaches are all symptoms of an unnecessarily complex and inefficiently constructed cybersecurity world. Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has implemented a new cybersecurity services approach, business and engagement model that transforms the way cybersecurity is consumed and applied. Optiv’s innovative approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change, by providing new consumption and outcome-based consulting services and cybersecurity solutions that ultimately achieve higher performance and reduced overall operational costs.

Specifically, the company is launching the following to more tightly align its breadth of capabilities and client-centric approach, to bring to market more focused global cybersecurity solutions that encompass people, process and technology.

  • Newly launched Global Services and Operations Organization – Optiv has redesigned its services approach centered on client-focused outcomes and is delivering global capabilities to assist clients along their cybersecurity journeys. The company’s breadth of services addresses the full lifecycle of client security needs – with newly launched business lines for Advisory, Integration & Innovation, and CyberOperations - providing global clients with the required focus and scale to execute on full end-to-end cyber risk, cyber digital and cybersecurity projects and programs.
  • Cyber-as-a-Service (CaaS TM ) Platform – designed to ensure organizations benefit from fully-integrated solutions that scale on-demand with business needs and automatically adapt to shifting business requirements. This approach enables Optiv to deliver complex and integrated solutions with an innovative integrated technology stack focused on client outcomes. Optiv’s new CaaSTM offerings can be consumed alone, or combined with Optiv’s advisory, integration or managed services to harden security fundamentals across four critical areas of modern business risk:
    • Risk management and compliance, including resilience and assurance;
    • Cyber digital transformation, including cloud, orchestration, automation and big data;
    • Threat management, including protection, detection and response; and
    • Identity and data management.
  • Global Services Demand (GSD) Organization – Coordinating Partner and Teaming Delivery Model – Optiv created GSD to provide clients with the optimal mix of centralized oversight and buying power, and localized technical resources and expertise. This new engagement model also brings together a seasoned team of regionally-focused senior technical services executives to give clients an important engagement layer atop Optiv’s more than 1,300 deeply skilled and specialized cybersecurity delivery practitioners. These executives serve as global coordinating partners for our clients, acting as a single point of accountability to drive excellence for complex end-to-end cybersecurity services and solutions.

“After more than 40 years since the first virus was launched, the approach to addressing cybersecurity issues has followed the same action and response formula. The challenge is that the world has changed, while the approach to cybersecurity has not kept pace,” said Chad Holmes, chief services and operations officer. “Industries are being completely reinvented – through digital transformation, cloud and data models, Artificial Intelligence (AI), globalization and much more – while cybersecurity gaps expand as symptoms of a historical approach to a new and different business model.”

Holmes continued, “Our new Cyber-as-a-Service consumption model, which we are launching based on client feedback and to meet growing market demand, strongly complements our traditional services model. It enables clients to have a choice in their cybersecurity consumption model, and thereby transform their organizational cybersecurity approach, while benefiting from the same cloud economics that have been used to transform entire industries. This custom developed, innovative and integrated approach provides organizations with increased flexibility and choice in how they procure cybersecurity – from standalone tools to integrated solutions – addressing complex security problems and delivering better alignment to unique business requirements. Optiv is extremely excited to bring to market our new Cyber-as-a-Service, integrated business services and client engagement models, that will increase our ability to provide clients with the right global resources at the right time so that we can truly serve their best interests.”

Please visit our website for more information about our cybersecurity solutions and capabilities.

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: www.optiv.com/resources/blog

About Optiv Security

Optiv is a global cybersecurity solutions integrator – a “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organizations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com .

Contact:

Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye